ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER

被引：0
|
作者：
Pimentel, Villar M. A. [1 ]
Anguita, Arance M. M. [1 ]
Almagro, Torres F. [1 ]
Lopez, Lopez J. A. [1 ]
机构：
[1] Hosp Univ Jaen, Jaen, Spain
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-006
引用
收藏
页码：337 / 337
页数：1
相关论文
共 50 条
  • [1] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
  • [2] The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
    Moreno, Laura
    Perez, Cristina
    Zabaleta, Aintzane
    Manrique, Irene
    Alignani, Diego
    Ajona, Daniel
    Blanco, Laura
    Lasa, Marta
    Maiso, Patricia
    Rodriguez, Idoia
    Garate, Sonia
    Jelinek, Tomas
    Segura, Victor
    Moreno, Cristina
    Merino, Juana
    Rodriguez-Otero, Paula
    Panizo, Carlos
    Prosper, Felipe
    San-Miguel, Jesus F.
    Paiva, Bruno
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 3176 - 3187
  • [3] Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma
    Hong, Augustine
    Eduafo, Augusta
    Schmikla, Hannah
    Brown, George
    Ravi, Gayathri
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2020, 136
  • [4] The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Petrucci, Maria Teresa
    Vozella, Federico
    CELLS, 2019, 8 (12)
  • [5] Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)
    Moreno, Laura
    Zabaleta, Aintzane
    Alignani, Diego
    Ajona, Daniel
    Lasa, Marta
    Maiso, Patricia
    Jelinek, Tomas
    Segura, Victor
    Delgado, Jose Antonio
    Rodriguez-Otero, Paula
    Prosper, Felipe
    San Miguel, Jesus
    Paiva, Bruno
    BLOOD, 2016, 128 (22)
  • [6] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhe Zhu
    Kairui Hong
    Yefang Ke
    Annals of Hematology, 2023, 102 : 1961 - 1962
  • [7] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhu, Zhe
    Hong, Kairui
    Ke, Yefang
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1961 - 1962
  • [8] Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients
    Zappaterra, Arianna
    Civettini, Ivan
    Cafro, Anna Maria
    Pezzetti, Laura
    Pierini, Silvia
    Anghilieri, Michela
    Bellio, Laura
    Bertazzoni, Paola
    Grillo, Giovanni
    Minga, Periana
    Pioltelli, Maria L.
    Ravano, Emanuele
    Sassone, Marianna
    V. Vigano, Clara
    Volpato, Elisabetta B.
    Gambacorti-Passerini, Carlo
    Rossini, Silvano
    Cairoli, Roberto
    Crocchiolo, Roberto
    BLOOD TRANSFUSION, 2024, 22 (04) : 328 - 337
  • [9] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
    Shah, Bhavesh
    Gray, Joy
    Abraham, Ivo
    Chang, Melody
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
  • [10] SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma
    An, Gang
    Jiang, Hua
    Acharya, Chirag
    Zhong, Mike Y.
    Cai, Ti
    Yang, Guang
    Song, Zhili
    Theilhaber, Joachim
    Adrian, Francisco
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
12345